Top Markets
Coin of the day
Clarity Pharmaceuticals Ltd Clarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Ltd

CU6
Rang in Aktien #11774
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company,... Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.
Aktienkurs
$1.77
Zuletzt synchronisiert: 2026-08-28
Marktkapitalisierung
$660.45M
Veränderung (1 Tag)
7.26%
Veränderung (1 Jahr)
-9.15%
Land
AU
Handel Clarity Pharmaceuticals Ltd (CU6)

Kategorie

Kursverlauf für Clarity Pharmaceuticals Ltd (CU6)
Höchster Schlusskurs: $1.83 am 2026-08-01

Niedrigster Schlusskurs: $1.06 am 2021-08-01
Kursverlauf der Aktie von Clarity Pharmaceuticals Ltd von 2021 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 4.14%
2025 -32.14%
2024 182.71%
2023 71.64%
2022 17.37%
2021 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$233.52 -4.71%
IE
$15.30 -23.07%
CN
$520.74 6.34%
CH
$164.39 -9.49%
CH
$2.30 -28.59%
CN